I guess my statement that drug companies are only interested in long term treatments was a bit sensational, but as we both agree, they need a return on their in

I guess my statement that drug companies are only interested in long term treatments was a bit sensational, but as we both agree, they need a return on their investment. I understand that developing drugs is both intellectually hard and extremely expensive, but there are in my view a few benefits that (super)national collaborations have over private companies: - you only need one cure, so the work only needs to be done successfully once (competition is in this case potentially wasteful) - knowledge and good people are pooled (not hoarded by the companies able to offer the best compensation) - access to larger sources of funding for individual projects - knowledge from failed projects could be publicly disseminated instead of locked up in the company's archives - no need to turn a profit The usual arguments I hear against state- or superstate-run organisations over the private sector is, as others have said here, the perceived wastes of resources when projects don't appear to be on a successful track: a private company would cancel early to avoid more waste, whereas a publicly funded organisation wouldn't necessarily do so as the project managers aren't incentivised by shareholder value. However, it seems to be to be just a case of having the right incentives. If they were instead tasked with improving patient outcomes measured over, I don't know, 10 years, then that could be a valid reason to use to cancel research that doesn't seem to be going anywhere ("it doesn't seem like this drug, even if it passes trials, will make a meaningful improvement in patient outcomes"). Another aspect of public organisations could be that the scientists in charge of the research would have their own reputation to consider, instead of that of the company. It would be in their own interest for costly projects to fail quickly if they go nowhere. Here's a thought: would it work if such a public organisation could underwrite the research of private drug companies? These companies could then be paid a "non finders fee" for failed drug projects that nevertheless showed significant promise, in return for low-cost access to the successful ones, and of course public sharing of the reasons why the drug failed. Would the economics of such a system work, or would drug companies find ways to game the system?